Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human , Mouse , Rat|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from the region surrounding the phosphorylated Tyr1086 residue of the human, mouse, rat, and pig epidermal growth factor receptor (EGFr) protein.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Immunocytochemistry (ICC)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (IHC)||Assay Dependent|
|Immunoprecipitation (IP)||0.1-0.5 µg/ml|
|Western Blot (WB)||0.1-0.5 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin, Frozen) (IHC (P, F))||See 3 publications below|
Epidermal Growth Factor Receptor (EGFR) is a 175 kDa transmembrane glycoprotein belonging to tyrosine kinase superfamily. It acts as a receptor for epidermal growth factor (EGF) family proteins. Binding of EGFR to its ligands causes autophosphorylation of tyrosine kinase followed by activation of signal transduction pathways connected to cell proliferation and differentiation. Tyrosine 1068 present within the cytoplasmic domain of the receptor is a major autophosphorylation site that allows binding of Grb2 and activation of the Ras-Raf-ERK1 and ERK2 signaling pathway.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
||Fenton TR,Nathanson D,Ponte de Albuquerque C,Kuga D,Iwanami A,Dang J,Yang H,Tanaka K,Oba-Shinjo SM,Uno M,Inda MM,Wykosky J,Bachoo RM,James CD,DePinho RA,Vandenberg SR,Zhou H,Marie SK,Mischel PS,Cavenee WK,Furnari FB||Proceedings of the National Academy of Sciences of the United States of America (109:14164)||2012|
Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.
||Prudkin L,Liu DD,Ozburn NC,Sun M,Behrens C,Tang X,Brown KC,Bekele BN,Moran C,Wistuba II||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (22:668)||2009|
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
||Tsao AS,Tang XM,Sabloff B,Xiao L,Shigematsu H,Roth J,Spitz M,Hong WK,Gazdar A,Wistuba I||Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (1:231)||2006|
ERBB1, wa-2, wa2, ERBB, Erbb, Errp, Errb1, Wa5, AI552599, HER1, mENA, ErbB-1, 9030024J15Rik, PIG61
EGFR-related peptide, Epidermal growth factor receptor formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1), avian erythroblastic leukemia viral (v-erbB) oncogene homolog, epidermal growth factor receptor, epidermal growth factor receptor, formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1), avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, waved 2, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1, EC 184.108.40.206, ERBB1, Epidermal growth factor receptor precursor, Receptor protein-tyrosine kinase ErbB-1, kinase EGFR